These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31817395)

  • 1. Risk of Acute Myocardial Infarction Among New Users of Allopurinol According to Serum Urate Level: A Nested Case-Control Study.
    Rodríguez-Martín S; de Abajo FJ; Gil M; González-Bermejo D; Rodríguez-Miguel A; Barreira-Hernández D; Mazzucchelli R; García-Lledó A; García-Rodríguez LA
    J Clin Med; 2019 Dec; 8(12):. PubMed ID: 31817395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allopurinol use and risk of non-fatal acute myocardial infarction.
    de Abajo FJ; Gil MJ; Rodríguez A; García-Poza P; Álvarez A; Bryant V; García-Rodríguez LA
    Heart; 2015 May; 101(9):679-85. PubMed ID: 25561685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of acute myocardial infarction among new users of chondroitin sulfate: A nested case-control study.
    Mazzucchelli R; Rodríguez-Martín S; García-Vadillo A; Gil M; Rodríguez-Miguel A; Barreira-Hernández D; García-Lledó A; de Abajo FJ
    PLoS One; 2021; 16(7):e0253932. PubMed ID: 34252115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.
    Singh JA; Akhras KS; Shiozawa A
    Arthritis Res Ther; 2015 May; 17(1):120. PubMed ID: 25963969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
    Cutolo M; Cimmino MA; Perez-Ruiz F
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of acute myocardial infarction among new users of bisphosphonates: a nested case-control study.
    Mazzucchelli R; Rodríguez-Martín S; García-Vadillo A; Crespí-Villarías N; Gil M; Rodriguez-Miguel A; Barreira D; Garcia-Lledó A; de Abajo FJ
    Osteoporos Int; 2020 Dec; 31(12):2403-2412. PubMed ID: 32662036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum urate levels and gout flares: analysis from managed care data.
    Sarawate CA; Patel PA; Schumacher HR; Yang W; Brewer KK; Bakst AW
    J Clin Rheumatol; 2006 Apr; 12(2):61-5. PubMed ID: 16601538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
    Halpern R; Mody RR; Fuldeore MJ; Patel PA; Mikuls TR
    Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial.
    Tanaka A; Taguchi I; Teragawa H; Ishizaka N; Kanzaki Y; Tomiyama H; Sata M; Sezai A; Eguchi K; Kato T; Toyoda S; Ishibashi R; Kario K; Ishizu T; Ueda S; Maemura K; Higashi Y; Yamada H; Ohishi M; Yokote K; Murohara T; Oyama JI; Node K;
    PLoS Med; 2020 Apr; 17(4):e1003095. PubMed ID: 32320401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system.
    Rashid N; Coburn BW; Wu YL; Cheetham TC; Curtis JR; Saag KG; Mikuls TR
    J Rheumatol; 2015 Mar; 42(3):504-12. PubMed ID: 25512479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of ischaemic stroke among new users of glucosamine and chondroitin sulphate: a nested case-control study.
    Mazzucchelli R; Rodríguez-Martín S; Crespí-Villarías N; García-Vadillo A; Gil M; Izquierdo-Esteban L; Rodríguez-Miguel A; Barreira-Hernández D; Fernández-Antón E; García-Lledó A; Pascual A; Vitaloni M; Vergés J; de Abajo FJ
    Ther Adv Musculoskelet Dis; 2022; 14():1759720X221113937. PubMed ID: 35923649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Urate Level on Cardiovascular Risk in Allopurinol Treated Patients. A Nested Case-Control Study.
    Søltoft Larsen K; Pottegård A; Lindegaard HM; Hallas J
    PLoS One; 2016; 11(1):e0146172. PubMed ID: 26751377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.
    Hosoya T; Ogawa Y; Hashimoto H; Ohashi T; Sakamoto R
    J Clin Pharm Ther; 2016 Jun; 41(3):290-7. PubMed ID: 27109450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
    Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
    Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the Relationship Between Serum Uric Acid Levels and Cardiovascular Events in Patients With Gout: A Retrospective Analysis Using Electronic Medical Record Data.
    Essex MN; Hopps M; Bienen EJ; Udall M; Mardekian J; Makinson GT
    J Clin Rheumatol; 2017 Apr; 23(3):160-166. PubMed ID: 28248798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open-label, 6-month study of allopurinol safety in gout: The LASSO study.
    Becker MA; Fitz-Patrick D; Choi HK; Dalbeth N; Storgard C; Cravets M; Baumgartner S
    Semin Arthritis Rheum; 2015 Oct; 45(2):174-83. PubMed ID: 26190562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Allopurinol on Cardiovascular Outcomes in Hyperuricemic Patients: A Cohort Study.
    Larsen KS; Pottegård A; Lindegaard HM; Hallas J
    Am J Med; 2016 Mar; 129(3):299-306.e2. PubMed ID: 26589484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
    Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL
    Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of allopurinol on the glomerular filtration rate of children with chronic kidney disease.
    Ghane Sharbaf F; Assadi F
    Pediatr Nephrol; 2018 Aug; 33(8):1405-1409. PubMed ID: 29549464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.